Nifty Weekly Outlook: Reversal confirmed, big moves expected around August 8, says Harshubh Shah
FPIs sold equities worth Rs 31,988 crore in July 2025 alone.
Total FPI outflow for the year till August 1 stands at Rs 1,31,876 crore — reflecting sustained bearishness by global investors.
Recap: July 28 – August 1
Live Events
July 29: Nifty opened near 24,600, then rallied over two sessions to hit 24,950+, gaining over 250 points from the low.
July 28: Price action remained within the 24,850–24,676 range.
July 29: Day's high was 24,847.15 — nearly hitting key resistance at 24,850.
July 31: Nifty bounced off 24,805 support to reach 24,956.50, brushing against the 24,980 zone.
August 1: Intraday low of 24,535.05 matched the projected support of 24,538.
Time cycle precision: Intraday predictions hit the mark
July 28: High at 10:20 AM; low around 2:15 PM
July 29: Low at open (9:15 AM); rally started at 10:20 AM, gained momentum by 12:50 PM
July 30: Day high around 11:35 AM; swings near 12:50 PM and 2:40 PM
July 31: Selling spiked around 2:40 PM, as forecasted
August 1: Minor swing high observed near 1:35 PM
Key levels to watch
Intraday time clusters for the week
Monday, Aug 4: 9:20 AM, 11:35 AM, 12:15 PM
Tuesday, Aug 5: 10:10 AM, 11:25 AM, 2:35 PM
Wednesday, Aug 6: 9:20 AM, 10:20 AM, 11:35 AM, 12:15 PM, 2:10 PM
Thursday, Aug 7: 9:15 AM, 10:00 AM, 11:15 AM, 12:15 PM
Friday, Aug 8: 9:20 AM, 10:20 AM, 11:25 AM, 1:25 PM
Outlook: August 4–8
Conclusion
(You can now subscribe to our
(You can now subscribe to our ETMarkets WhatsApp channel
The Indian equity market ended the week through August 1, 2025, on a cautious note, marking its fifth consecutive weekly loss.The Nifty50 index fell over 1% during the week, despite a midweek rebound that aligned well with earlier technical forecasts.However, amid the ongoing selling pressure, July 29 emerged as a turning point, validating last week's projection that highlighted the date as a potential inflection point.Foreign Portfolio Investors (FPIs) continued to exit Indian equities. According to NSDL data:Despite early-week weakness, markets staged a strong reversal from July 29:Time-based forecasts delivered high-accuracy calls. Key intraday swings aligned closely with projected time windows:These time clusters offered tactical entry/exit opportunities for active traders.24,535 / 24,482 / 24,458 / 24,382 / 24,331 / 24,143 / 23,87524,648 / 24,677 / 24,806 / 24,856 / 24,978 / 25,083 / 25,145These are key pivots. Market behavior around these points may define short-term direction.Watch for increased volatility near these time slots:These may serve as key reversal or momentum windows.While July 29 confirmed a short-term reversal, the next pivotal dates are August 8 and August 11. These sessions may set the tone for the market's next leg — either continuing the recovery or triggering another sell-off.The high and low of August 8 could form a breakout structure, making it a critical day for positional traders to watch. Also, August 6 and 7 are expected to be highly volatile for intraday moves due to overlapping time clusters.The technical setup has shifted. With July 29 acting as a springboard and August 8 positioned as a potential breakout date, traders must stay nimble.Use the support-resistance zones and time clusters as tactical markers, while watching for key directional cues early in the second week of August.(The author Harshubh Mahesh Shah is Director, Wealthview Analytics Pvt Ltd. SEBI Registration – INH000009676)(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
6 minutes ago
- Business Standard
Gujarat remains top exporting state in FY25 with ₹9.83 trn exports: FIEO
Gujarat retained its position as India's top exporting state in 2024-25, with outbound shipments worth Rs 9.83 lakh crore, accounting for 26.6 per cent of the country's total exports, FIEO said on Tuesday. It said despite a marginal dip from the previous year, Gujarat's exports remained significantly ahead of all other states, nearly Rs 4.3 lakh crore more than Maharashtra (Rs 5,57,271 crore), the second-ranked state. Maharashtra is followed by Tamil Nadu, Karnataka, Uttar Pradesh, Andhra Pradesh and Telangana, according to the analysis of the Federation of Indian Export Organisations (FIEO). "In 2024-25, Gujarat reaffirmed its leadership as India's top exporting state, accounting for Rs 9.83 lakh crore, which is 26.6 per cent of the country's total exports," it said. It added that Gujarat's export dominance continues to be driven by a few high-performing districts, with Jamnagar maintaining a commanding lead at Rs 3.63 lakh crore, largely owing to its petroleum and refinery exports. Jamnagar contributes over one-third of the state's total. The top five export commodities from the state are Petroleum Products, Gems and Jewellery, Organic Chemicals, Pharmaceuticals, and Engineering Goods (Machinery). In 2024-25, Uttar Pradesh contributes Rs 1.86 lakh crore to India's total exports of Rs 37.02 lakh crore. This accounts for 5 per cent of the country's total exports, positioning Uttar Pradesh as an important player in India's export landscape. "Uttar Pradesh has demonstrated a commendable diversification in its export markets, reaching both traditional and emerging economies across continents," it said, adding that the US continues to be the top export destination of the state.
&w=3840&q=100)
Business Standard
6 minutes ago
- Business Standard
Britannia Q1 profit misses estimates, sees early signs of urban recovery
Britannia Industries posted first-quarter profit below estimates on Tuesday, but the Indian biscuit maker said urban consumption - dull for a few quarters - is picking up. The seller of 'Marie Gold' and 'Bourbon' biscuits joins other domestic consumer goods makers such as Hindustan Unilever and ITC in forecasting early signs of a recovery in urban demand, aided by easing local inflation. India's annual retail inflation slowed every month in the quarter, easing to a six-year low in June at 2.1 per cent. That helped spur a "marginal uptick in consumption across both urban and rural markets," said Varun Berry, managing director and chief executive. Britannia's quarterly sales grew 9.8 per cent to ₹4,535 crore ($516.5 million). The firm had previously flagged rise in popular demand for packaged food and confectionery items such as croissants, wafers and flavoured shakes - usually more likely to be bought on impulse. But total spends rose 10.4 per cent, led by a 15 per cent jump in raw material costs. Britannia has been hiking prices to partly offset the higher costs of raw materials such as cocoa, flour and palm oil. Profits in the reported quarter came in at ₹521 crore, up 3 per cent on-year, but below analysts' average estimate of ₹570 crore rupees, according to data compiled by LSEG.
&w=3840&q=100)
Business Standard
6 minutes ago
- Business Standard
Eris Lifesciences to tap Rs 5,000-cr insulin and semaglutide market in FY26
Ahmedabad-based Eris Lifesciences is looking to tap opportunities in the nearly Rs 5,000-crore Indian insulin market after Danish drugmaker Novo Nordisk announced the withdrawal of its insulin products from the market in April this year. 'We expect that Novo's cartridge inventory in the market will run out by October 2025. So this market opportunity is something that one can start monetising from the November–December time frame,' the company's executive director and chief executive officer (CEO), Krishnakumar Vaidyanathan, told Business Standard. He added that the timing fits Eris' plans, as the cartridge filling capability of its Bhopal unit will start becoming operational from January. Vial manufacturing has already been commissioned at the unit, with the company creating a strategic stock of insulins. This comes at a time when Eris is already the largest domestic player in insulins. The company had acquired the India formulations business of Biocon Biologics last year — including established insulin brands Basalog and Insugen. 'Before the Biocon deal, we had a couple of homegrown insulin brands in the market, which did a combined Rs 60 crore in revenue last year. Basalog and Insugen had combined revenues of Rs 200 crore at the time of acquisition,' he said. He added that, with this, the company's insulin franchise has become significantly larger, with a 10 per cent market share. Eris is also among the prominent drugmakers looking to roll out generic versions of the blockbuster molecule semaglutide once its patent expires around March next year. Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist used as an active pharmaceutical ingredient in medications for obesity management and Type-II diabetes. According to Eris' investor presentation for the June quarter of 2025–26 (Q1FY26), the company is on track to be among the first launches in India in March 2026. The company has initiated validation of synthetic semaglutide cartridges at its European Union (EU)-approved AMD injectables site. 'We are also planning the validation of the recombinant semaglutide in our Bhopal plant later this year,' he added. As far as the go-to-market strategy is concerned, the company said it is already in a strong position because of its dominant presence in insulins and prior presence in the GLP market with the launch of liraglutide in September last year. For Q1FY26, Eris Lifesciences recorded a 40 per cent year-on-year (Y-o-Y) rise in consolidated profit after tax (PAT) to Rs 125 crore. Revenue rose to Rs 773 crore during the June quarter against Rs 720 crore in the year-ago period.
